Research ExplorerPublicationsVenetoclax with azacitidine targets refractory MDS but spare...

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

Standard

Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. / Jilg, Stefanie; Hauch, Richard T; Kauschinger, Johanna; Buschhorn, Lars; Odinius, Timo O; Dill, Veronika; Müller-Thomas, Catharina; Herold, Tobias; Prodinger, Peter M; Schmidt, Burkhard; Hempel, Dirk; Bassermann, Florian; Peschel, Christian; Götze, Katharina S; Höckendorf, Ulrike; Haferlach, Torsten; Jost, Philipp J.

In: EXP HEMATOL ONCOL, Vol. 8, 16.04.2019, p. 9.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jilg, S, Hauch, RT, Kauschinger, J, Buschhorn, L, Odinius, TO, Dill, V, Müller-Thomas, C, Herold, T, Prodinger, PM, Schmidt, B, Hempel, D, Bassermann, F, Peschel, C, Götze, KS, Höckendorf, U, Haferlach, T & Jost, PJ 2019, 'Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose', EXP HEMATOL ONCOL, vol. 8, pp. 9. https://doi.org/10.1186/s40164-019-0133-1

APA

Jilg, S., Hauch, R. T., Kauschinger, J., Buschhorn, L., Odinius, T. O., Dill, V., Müller-Thomas, C., Herold, T., Prodinger, P. M., Schmidt, B., Hempel, D., Bassermann, F., Peschel, C., Götze, K. S., Höckendorf, U., Haferlach, T., & Jost, P. J. (2019). Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. EXP HEMATOL ONCOL, 8, 9. https://doi.org/10.1186/s40164-019-0133-1

Vancouver

Jilg S, Hauch RT, Kauschinger J, Buschhorn L, Odinius TO, Dill V et al. Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose. EXP HEMATOL ONCOL. 2019 Apr 16;8:9. https://doi.org/10.1186/s40164-019-0133-1

Bibtex

@article{bb85d662ecaa4c49bcf8f32682fdd546,
title = "Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose",
abstract = "Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.",
author = "Stefanie Jilg and Hauch, {Richard T} and Johanna Kauschinger and Lars Buschhorn and Odinius, {Timo O} and Veronika Dill and Catharina M{\"u}ller-Thomas and Tobias Herold and Prodinger, {Peter M} and Burkhard Schmidt and Dirk Hempel and Florian Bassermann and Christian Peschel and G{\"o}tze, {Katharina S} and Ulrike H{\"o}ckendorf and Torsten Haferlach and Jost, {Philipp J}",
year = "2019",
month = apr,
day = "16",
doi = "10.1186/s40164-019-0133-1",
language = "English",
volume = "8",
pages = "9",
journal = "EXP HEMATOL ONCOL",
issn = "2162-3619",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Venetoclax with azacitidine targets refractory MDS but spares healthy hematopoiesis at tailored dose

AU - Jilg, Stefanie

AU - Hauch, Richard T

AU - Kauschinger, Johanna

AU - Buschhorn, Lars

AU - Odinius, Timo O

AU - Dill, Veronika

AU - Müller-Thomas, Catharina

AU - Herold, Tobias

AU - Prodinger, Peter M

AU - Schmidt, Burkhard

AU - Hempel, Dirk

AU - Bassermann, Florian

AU - Peschel, Christian

AU - Götze, Katharina S

AU - Höckendorf, Ulrike

AU - Haferlach, Torsten

AU - Jost, Philipp J

PY - 2019/4/16

Y1 - 2019/4/16

N2 - Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.

AB - Patients with Myelodysplastic Syndromes (MDS) and secondary Acute Myeloid Leukemia (sAML) have a very poor prognosis after failure of hypomethylating agents (HMA). Stem cell transplantation is the only effective salvage therapy, for which only a limited number of patients are eligible due to age and comorbidity. Combination therapy of venetoclax and azacitidine (5-AZA) seems to be a promising approach in myeloid malignancies, but data from patients with HMA failure are lacking. Furthermore, a considerable concern of combination regimens in elderly AML and MDS patients is the toxicity on the remaining healthy hematopoiesis. Here, we report in vitro data showing the impact of venetoclax and 5-AZA, alone or in combination, in a larger cohort of MDS/sAML patients (n = 21), even after HMA failure (n = 13). We especially focused on the effects on healthy hematopoiesis and the impact on colony forming capacity as a parameter for long-term effects. To the best of our knowledge, we show for the first time that venetoclax in combination with capped dose of 5-AZA targets cell malignancies, while sparing healthy hematopoiesis.

U2 - 10.1186/s40164-019-0133-1

DO - 10.1186/s40164-019-0133-1

M3 - SCORING: Journal article

C2 - 31016067

VL - 8

SP - 9

JO - EXP HEMATOL ONCOL

JF - EXP HEMATOL ONCOL

SN - 2162-3619

ER -